Global Leading Market Research Publisher QYResearch announces the release of its latest report “Immunotoxicity Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Immunotoxicity Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
Pharmaceutical, biotechnology, and medical device companies face a persistent challenge: identifying whether a candidate drug, biologic, or material inadvertently disrupts immune system function before advancing to clinical trials. Unrecognized immunotoxicity—ranging from immunosuppression and hypersensitivity to life-threatening cytokine release syndrome (CRS)—has caused numerous late-stage failures, regulatory holds, and post-market withdrawals. Immunotoxicity Testing solves this pain point by providing systematic evaluation of whether a substance—such as a drug, biologic, chemical, or medical device material—interferes with the normal function, regulation, or integrity of the immune system. It identifies potential adverse immune effects, including suppression, stimulation, hypersensitivity, autoimmunity, or cytokine storm–like responses. With the explosive growth of immunomodulatory therapies (checkpoint inhibitors, CAR-T cells, bispecific antibodies) and increasing regulatory scrutiny from FDA, EMA, and ICH, immunotoxicity testing has evolved from a niche safety discipline into a non-negotiable component of drug development programs.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097976/immunotoxicity-testing
1. Market Size, Growth Trajectory & Core Keywords
The global market for Immunotoxicity Testing was estimated to be worth US$ 5,538 million in 2025 and is projected to reach US$ 12,610 million, growing at a CAGR of 12.7% from 2026 to 2032.
Core industry keywords integrated throughout this analysis include: Immunotoxicity Testing, In Vivo Immunotoxicity, In Vitro Immunotoxicity, Cytokine Storm Assessment, and Biologic Safety Evaluation.
2. Industry Segmentation: In Vivo vs. In Vitro Testing Approaches
From a methodological stratification viewpoint, immunotoxicity testing divides into two complementary approaches, each with distinct advantages and limitations:
- In Vivo Testing (animal-based): Uses rodent (typically mouse or rat) and non-rodent models to assess comprehensive immune function endpoints, including T-cell dependent antibody response (TDAR), natural killer (NK) cell activity, macrophage phagocytosis, and hypersensitivity reactions. In vivo testing remains the regulatory gold standard for ICH S8-compliant immunotoxicity evaluation, particularly for small molecule drugs and novel chemical entities (NCEs). However, growing pressure for animal welfare (3Rs: Replacement, Reduction, Refinement) is limiting adoption. Typical study duration ranges from 28 days to 6 months, costing US$150,000–500,000 per program.
- In Vitro Testing (cell-based): Employs human or animal-derived immune cells (peripheral blood mononuclear cells, PBMCs; dendritic cells; mast cells) to assess cytokine release, lymphocyte proliferation, complement activation, and immunophenotyping. In vitro assays offer higher throughput, lower cost (US$20,000–80,000 per panel), and human-relevant data without interspecies translation concerns. They are particularly valuable for biologics (monoclonal antibodies, fusion proteins) and CAR-T therapies where animal models poorly predict human CRS. Leading CROs have developed standardized panels (e.g., cytokine storm panel measuring IL-6, TNF-α, IFN-γ, IL-2, IL-10).
Segment by Type
- In Vivo Testing: Animal-based comprehensive immune function assessment (TDAR, NK activity, hypersensitivity).
- In Vitro Testing: Cell-based cytokine release, immunophenotyping, complement activation.
Segment by Application
- Biotechnology: Biologics, cell therapies, gene therapies, monoclonal antibodies.
- Pharmaceutical Industry: Small molecule drugs, NCEs, generics with immunotoxicity concerns.
- Others: Medical devices (implantable materials, drug-eluting stents), chemicals, agrochemicals.
3. Recent Industry Data (Last 6 Months) & Policy Drivers
According to new data from the Society of Toxicology (SOT) annual meeting and FDA’s Immunotoxicology working group reports (Q1–Q3 2025):
- Global immunotoxicity testing revenue increased 16.4% year-over-year, driven by 48 new biologic approvals in 2025 (including 12 bispecific antibodies and 6 CAR-T therapies) requiring enhanced immune safety packages.
- In vitro testing now accounts for approximately 45% of total immunotoxicity testing value, up from 38% in 2023, with the segment growing at 17.8% CAGR versus 9.2% for in vivo.
- Cytokine release syndrome (CRS) assessment is the fastest-growing assay type at 22.3% CAGR, as all T-cell engaging bispecifics and CAR-T products require FDA-mandated CRS evaluation before FIH (first-in-human) trials.
Policy impact: The ICH S8 guideline revision (Step 4 released October 2025) now explicitly recommends in vitro cytokine release assays for biologics with known T-cell engagement mechanisms, reducing reliance on non-human primate studies where possible. FDA’s 2025 draft guidance “Immunotoxicity Assessment for Cell and Gene Therapy Products” mandates enhanced immunophenotyping for CAR-T and gene-editing products, including assessment of vector-specific immune responses. The EU’s REACH regulation revision (effective January 2026) adds six new immunotoxicity endpoints for chemical registration, expanding the addressable market beyond pharmaceuticals.
4. Technical Challenges & Solution Differentiation
Three persistent technical barriers define competition in immunotoxicity testing services:
- Predictive accuracy of in vitro assays: While human PBMC-based cytokine release assays correlate well with clinical CRS for T-cell engagers (approximately 85% concordance), they perform poorly for antibody-dependent cellular cytotoxicity (ADCC)-mediated effects or complement-dependent cytotoxicity (CDC). Leading CROs like Charles River and Eurofins have developed whole-blood cytokine release assays and co-culture systems (PBMCs + target cells) improving predictive accuracy to >90%.
- Immunophenotyping standardization: Flow cytometry-based immunophenotyping (CD4+/CD8+ T-cell subsets, B-cells, NK cells, monocytes) suffers from inter-lab variability due to antibody clones, gating strategies, and instrument platforms. IQVIA and BioAgilytix have implemented standardized panel designs (following EuroFlow or CYTEF protocols) and cross-platform validation to ensure reproducibility across studies.
- Translating animal findings to humans: Rodent immune systems differ significantly from humans (e.g., TLR expression, cytokine profiles). Advanced CROs now offer humanized mouse models (NSG, NOG strains engrafted with human CD34+ hematopoietic stem cells) for biologics testing, though at 3–5x higher cost than standard models.
Exclusive industry insight: A 2025 industry survey (American Association of Pharmaceutical Scientists, July 2025) revealed that 41% of biologic developers experienced unexpected immunogenicity signals in Phase I/II trials that were not predicted by standard in vivo or in vitro immunotoxicity panels. This has driven demand for “immunogenicity risk assessment” as a distinct service line, with Charles River and Nelson Labs launching integrated immunotoxicity + immunogenicity packages (including anti-drug antibody detection, T-cell epitope mapping) at a 25–30% premium over standalone testing.
5. User Case Examples (In Vivo vs. In Vitro Segments)
- Case 1 – In vivo immunotoxicity testing (small molecule NCE): A pharmaceutical company developing a novel JAK inhibitor for autoimmune disease required ICH S8-compliant immunotoxicity assessment for regulatory submission. Using Altasciences’ in vivo platform, they conducted a 28-day rat study including TDAR (KLH immunization), NK cell activity, and immunophenotyping. Results showed dose-dependent immunosuppression at high doses, leading to clinical trial dose selection 40% lower than initially planned, avoiding potential safety risks in Phase I.
- Case 2 – In vitro immunotoxicity testing (bispecific antibody): A biotech company developing a CD3/CD20 bispecific for B-cell malignancies required FDA-mandated cytokine release assessment before FIH trial. Using Eurofins’ human PBMC-based cytokine release assay (measuring IL-6, TNF-α, IFN-γ, IL-2, IL-10 at 6, 24, 48 hours), they identified moderate CRS risk requiring step-up dosing. The in vitro data supported IND submission without non-human primate studies, saving US$1.2 million and 4 months of development time.
6. Competitive Landscape (Selected Key Players)
The immunotoxicity testing CRO market is concentrated among large, full-service CROs and specialized immunology laboratories:
Altasciences, BioAgilytix, BRT Laboratories, Charles River Laboratories, Eurofins, Intertek, IQVIA, Nelson Labs.
独家观察 (Exclusive strategic note): The immunotoxicity testing market is consolidating toward “integrated immunology” providers offering immunotoxicity, immunogenicity, and biomarker analysis under one roof. Charles River Laboratories acquired a cytokine profiling startup in Q3 2025, and IQVIA expanded its flow cytometry capabilities to 12 global sites. However, specialized boutique CROs (e.g., BioAgilytix for biologics immunotoxicity) maintain premium pricing (15–20% above large CROs) by offering faster turnaround (3–4 weeks vs. 6–8 weeks) and deeper immunology expertise. A capacity crunch is emerging for high-complexity assays (humanized mouse models, multi-parameter flow cytometry panels >20 markers), with lead times extending to 12–16 weeks—a gap that new entrants from Asia (e.g., WuXi AppTec, Crown Bioscience) are aggressively filling at 25–35% lower price points.
7. Forecast Outlook (2026–2032)
The convergence of high-parameter flow cytometry (30+ markers), single-cell sequencing, and AI-based immunotoxicity prediction will reshape the market by 2028. Over 50% of immunotoxicity testing programs are expected to incorporate microphysiological systems (immune-on-chip platforms) as in vivo alternatives, particularly for chemical safety assessment. Biologic developers should prioritize CROs offering (1) ICH S8-compliant TDAR and immunophenotyping, (2) human PBMC-based cytokine release panels with multiple timepoints, (3) regulatory filing support for FDA/EMA/PMDA submissions. The shift toward personalized immunotoxicity assessment (patient-derived PBMCs for autologous cell therapies) will sustain demand for flexible small-scale in vitro testing alongside traditional large-animal regulatory packages.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
